Study on N-acetylcysteine Versus Placebo to Reduce Opioid Use After Laparoscopic or Robotic Hysterectomy

What this Trial Is About

Researchers are evaluating the impact of intravenous n-acetylcysteine NAC compared to a placebo on opioid use in females aged 18 and older undergoing laparoscopic or robotic, partial or full hysterectomy procedures. This phase 3 trial aims to understand how NAC affects pain and opioid consumption after surgery. Participants will be randomly assigned to receive either NAC at a dose of 150 mgkg up to 15,000 mg or a placebo solution 0.45% NaCl or D5W administered through an IV for 60 minutes at the start of their hysterectomy procedure. The study uses a triple-blind design, meaning patients, healthcare providers, and researchers will not know who receives NAC or placebo during the treatment. During the 72 hours following the procedure, participants will report their pain levels and record any pain medications taken. Researchers will closely monitor opioid consumption and pain scores to assess the effects of NAC. The study includes careful safety monitoring and will continue until December 2026.

NAC vs Placebo on Opioid Use for Hysterectomy